Cyclo Therapeutics is a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. Co.'s primary drug candidate, Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), is used as a treatment for Niemann-Pick Type C disease (NPC). NPC is a cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. Co. is also exploring the use of cyclodextrins in the treatment of Alzheimer's disease. Co. sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. We show 15 historical shares outstanding datapoints in our CYTH shares outstanding history coverage, used to compute CYTH market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CYTH market cap history over the course of time is important for investors
interested in comparing CYTH's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CYTH versus a peer is one thing; comparing
CYTH market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CYTH can fluctuate over the course of history.
With this page we aim to empower investors researching CYTH by allowing them to research the CYTH market cap history. |
Free CYTH Email Alerts:
Video: The Importance of Market Cap
